Biotechnology
Company Overview of Alopexx Pharmaceuticals, LLC
Company Overview
Alopexx Pharmaceuticals, LLC develops and explores target based immunotherapies for the treatment and prevention of Methicillin-resistant S. Aureus (MRSA) and other serious infections. It offers mAb F598, a human monoclonal antibody, which serves as an alternative to antibiotics against MRSA and other Staphylococcus aureus infections. Alopexx Pharmaceuticals was incorporated in 2006 and is based in Cambridge, Massachusetts.
50 Buckingham Street
Cambridge, MA 02138
United States
Founded in 2006
Key Executives for Alopexx Pharmaceuticals, LLC
Similar Private Companies By Industry
| Company Name | Region |
| Global Clinicals, Inc. | United States |
| Neurotrope Bioscience, Inc. | United States |
| Swift Biosciences, Inc. | United States |
| Navitas Pharma, Inc. | United States |
| BioCee, Inc. | United States |
Recent Private Companies Transactions
| Type Date |
Target | |
| No transactions available in the past 12 months. | ||
Most Searched Private Companies
| Company Name | Geographic Region |
| NYC2012, Inc. | United States |
| Bertelsmann AG | Europe |
| Lawyers Committee for Civil Rights Under Law | United States |
| Rush University | United States |
| Greater Houston Partnership | United States |
Post a JobJobs
- New York, NY | William Blair Company, L.L.CPosted: Apr 19
- New York, NY | Robert W. BairdPosted: Apr 21
- San Francisco, CA | Confidential Biotechnology CompanyPosted: May 13
- Waltham, MA | Nova BiomedicalPosted: May 16
Sponsored Financial Commentaries
Sponsored Links
To contact Alopexx Pharmaceuticals, LLC, please visit www.alopexx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
